Hostname: page-component-848d4c4894-p2v8j Total loading time: 0.001 Render date: 2024-05-23T12:45:50.986Z Has data issue: false hasContentIssue false

Treatment of the attention deficit disorder (residual type) with moclobemide

Published online by Cambridge University Press:  16 April 2020

L Chamorro
Affiliation:
Section Psiquiatria, Hospital General Universitario de Guadalajara, Donantes de sangre s/n, 19002Guadalajara, Spain
I Lopez
Affiliation:
Section Psiquiatria, Hospital General Universitario de Guadalajara, Donantes de sangre s/n, 19002Guadalajara, Spain

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letter to the editor
Copyright
Copyright © Elsevier, Paris 1995

References

Parquet, PJServant, DBailly, Det al.Monoamine oxidase inhibitor in the treatment of attention deficit disorder of residual type.A propos of a case Encephale 14/6 1988 439–41Google Scholar
Wenker, PHGarfinkel, BDAttention Deficit Hyperactivity Disorder: Adult Manifestations Kaplan, HISadock, BJ 5th edComprehensive Textbook of Psychiatryvol 2 Baltimore: Williams and Wilkins, 1989; 1837–41Google Scholar
Biederman, JNewcorn, JSpnah, SComorbidity of Attention Deficit Hyperactivity Disorder with conduct, depressive, anxiety and other disorders Am J Psychiatry 148/5 1991 564–77Google ScholarPubMed
Shakim, WOAsarnow, RFHess, E et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state Compr Psychiatry 31/5 1990 416–25CrossRefGoogle Scholar
Trott, GEFriese, HJMenzel, Met al.Use of Moclobemide in children with attention deficit hyperactivity disorder. Psyche-pharmacology 1992; 106: S134–6CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.